2696 — Shanghai Henlius Biotech Share News
0.000.00%
Last trade - 00:00- HK$35.72bn
- HK$39.39bn
- CNY6.67bn
Brief: Shanghai Henlius Biotech Inc Says NDA For Biosimilar Of Denosumab HLX14 Accepted By NMPA
Brief: Shanghai Henlius Biotech Says Hansizhuang Granted Breakthrough Therapy Designation For Gastric Cancer By NMPA
Organon rises after US FDA clears first biosimilar for breast cancer
Brief: Shanghai Henlius Biotech Says FDA Grants Orphan-Drug Designation To HLX43
Brief: Phase 3 Clinical Trial Of Hansizhuang Plus Chemotherapy Meets Primary Endpoint In Neoadjuvant/Adjuvant Gastric Cancer, Greenlighting Early NDA Submission
Brief: Shanghai Henlius Biotech Says Phase 3 Study Of Hansizhuang For Gastric Cancer Met Primary Endpoint
Brief: Shanghai Henlius Biotech Says NMPA Approves Phase 1B/2 Trial For Hlx43 And Hlx07
Media: Fosun's Henlius is said in talks with J&J, Roche on cancer drug - Bloomberg News
Brief: Shanghai Henlius Biotech SAys FDA Approves IND Application For Henlius' Biosimilar Hlx17
Brief: HKEX Announces Disciplinary Action Against Shanghai Henlius Biotech
Brief: Shanghai Henlius Biotech Inc Says U.S. FDA Approves HLX14 Products For Eight Indications
Brief: Shanghai Henlius Biotech Logs H1 Net Income RMB 390.1 Mln
Brief: UBS Group AG's Long Position In H-Shares Of Shanghai Henlius Biotech Decreases To 3.53% On August 13 From 5.91% - HKEX
Brief: Shanghai Henlius Biotech Says New Drug Application For Recombinant Anti-VEGF-Humanised Monoclonal Antibody Injection HLX04-O Accepted By NMPA
Brief: Shanghai Henlius Biotech Says FDA Approves HLX43 For Phase 1 Clinical Trial For Treatment Of Thymic Carcinoma
Brief: Fosun Pharmaceutical's Unit Signs Licensing Agreement With FBD Biologics
Brief: Shanghai Henlius Biotech Signs License Agreement With FBD for HCB101
Brief: Shanghai Henlius Biotech Says Orphan-Drug Designation For Hlx22 Granted By European Commission
Brief: Shanghai Henlius Biotech Says Inclusion As Constituent In MSCI- Global Small Cap Indexs